Search Results
Your search for ,NhS matches 324 pages
Showing 101 - 150Second-Line FOLFOX vs Active Symptom Control in Advanced Biliary Tract Cancer
In the phase III ABC-06 trial reported in The Lancet Oncology, Angela Lamarca, PhD, and colleagues found that second-line FOLFOX (leucovorin, fluorouracil [5-FU], and oxaliplatin) produced a statistically significant improvement in median overall survival vs active symptom control in patients with...
Expert Point of View: Elizabeth Smyth, MD
The overall survival benefit for PD-L1 CPS ≥ 5 tumors in CheckMate 649 is a game-changer. An oxaliplatin doublet plus chemotherapy should become a standard of care for these patients,” according to Elizabeth Smyth, MD, an oncology consultant at Cambridge University Hospital NHS Foundation Trust in...
Nivolumab Plus Chemotherapy: New Standard of Care in Advanced Gastric Cancer?
As first-line treatment for advanced gastric cancer, nivolumab plus chemotherapy leads to significantly improved progression-free and overall survival over chemotherapy alone, investigators reported during a Presidential Symposium of the European Society for Medical Oncology (ESMO) Virtual Congress ...
Some Patients With Lung Cancer Report Feeling Uninformed About Their Disease, Uninvolved With Their Treatment
More than 1 in 10 patients with lung cancer do not know what type of tumor they have, according to data from a 17-country study carried out by the Global Lung Cancer Coalition (GLCC) presented by Beattie et al at the European Lung Cancer Virtual Congress 2021 (Abstract 209P_PR). Nearly one in five...
KEYNOTE-177: New Analysis Confirms Benefit of Pembrolizumab vs Chemotherapy in Microsatellite Instability–High Advanced Colorectal Cancer
In an updated analysis of the pivotal phase III KEYNOTE-177 trial of pembrolizu-mab for microsatellite instability–high (MSI-H) metastatic colorectal cancer, the benefit of first-line pembrolizumab continued beyond disease progression on the subsequent line of treatment, despite a high crossover to ...
CONFIRM Trial Reports Improvement in Survival With Nivolumab in Relapsed Malignant Mesothelioma
For the first time, a treatment has been shown to improve overall survival in heavily pretreated patients with relapsed malignant mesothelioma. In the phase III CONFIRM trial, single-agent nivolumab led to a significant improvement in both overall and progression-free survival, according to...
KEYNOTE-177: New Analysis Confirms Benefit of Pembrolizumab vs Chemotherapy in Microsatellite Instability–High Advanced Colorectal Cancer
In an updated analysis of the pivotal phase III KEYNOTE-177 trial in microsatellite instability–high (MSI-H) metastatic colorectal cancer, the benefit of first-line pembrolizumab continued beyond disease progression on the subsequent line of treatment, despite a high crossover to immunotherapy for...
Phase II CodeBreak 100 Validates Benefit of KRAS Inhibitor Sotorasib in Advanced Lung Cancer
The registrational phase II CodeBreak 100 trial has validated the power of KRAS inhibition with sotorasib (AMG 510) in advanced non–small cell lung cancer (NSCLC).1 In a follow-up to the groundbreaking findings of the phase I trial, the phase II cohort has now shown a durable response rate of...
Bone Metastatic Burden and Survival Outcomes With Prostate Radiotherapy for Newly Diagnosed Metastatic Disease
In an analysis from the STAMPEDE trial reported in JAMA Oncology, Ali et al found that a lower number of bone metastases was associated with improved overall and failure-free survival in patients receiving prostate radiotherapy for newly diagnosed M1 metastatic prostate cancer. Study Details The...
Hypofractionated vs Conventionally Fractionated Radiotherapy for Locally Advanced Bladder Cancer
In an individual patient-level meta-analysis of two phase III trials reported in The Lancet Oncology, Choudhury et al found that a hypofractionated radiotherapy regimen was associated with improved invasive locoregional control and similar toxicity vs a standard fractionation regimen in patients...
Comparison of Imaging Regimens for Stage I Seminoma After Orchiectomy
Men who have had treatment for early-stage testicular cancer may benefit from fewer monitoring scans, freeing them from some of the harmful radiation that comes from computerized tomography (CT) imaging, according to results from the phase III TRISST clinical trial presented by Joffe et al at the...
Enfortumab Vedotin-ejfv Prolongs Survival in Patients With Metastatic Urothelial Carcinoma
Treatment with the antibody-drug conjugate enfortumab vedotin-ejfv has been found to significantly increase survival of patients with metastatic urothelial carcinoma, according to results from the phase III EV-301 clinical trial. These findings were presented by Thomas Powles, MD, PhD, and...
Stereotactic Ablative Body Radiotherapy in Extracranial Oligometastatic Cancers
In a registry-based observational study reported in The Lancet Oncology, Anastasia Chalkidou, PhD, and colleagues found that stereotactic ablative body radiotherapy (SABR) was associated with high overall survival and low rates of toxicity in patients with extracranial oligometastatic cancers. The...
Changes in Radiotherapy Use in England During the First Peak of the COVID-19 Pandemic
In a population-based study reported in The Lancet Oncology, Spencer et al found that mean weekly radiotherapy courses for cancer and attendance for receipt of fractions declined significantly during the first peak of the COVID-19 pandemic in England. However, use of hypofractionated radiotherapy...
WCLC Press Briefing Focuses on the Connection Between Lung Cancer and COVID-19
On February 27, 2020, the Journal of Thoracic Oncology published a case study that described two patients from Wuhan, China, who had recently underwent lung lobectomies for adenocarcinoma and were retrospectively found to have had COVID-19 at the time of surgery. Eleven months later, the lung...
Nivolumab Monotherapy Improves Survival in Patients With Relapsed Malignant Mesothelioma
In patients with relapsed malignant mesothelioma, treatment with single-agent nivolumab led to a significant improvement in both overall and progression-free survival in the phase III CONFIRM trial. These findings were presented by Dean A. Fennell, FRCP, PhD, Professor and Chair of Thoracic Medical ...
Phase II CodeBreak 100 Validates Early Benefit for KRAS Inhibitor in NSCLC
The phase II CodeBreak 100 trial has validated the power of KRAS inhibition with sotorasib (AMG 510) in patients with advanced non–small cell lung cancer (NSCLC). In a follow-up to phase I data, the phase II cohort of the study has now shown a durable response rate of 37.1%, a disease control rate...
Adjuvant Doublet Chemotherapy for High-Risk Stage II Colorectal Cancer: 3- or 6- Month Duration?
In an analysis of data from the IDEA collaboration reported in the Journal of Clinical Oncology, Timothy J. Iveson, MD, FRCP, and colleagues found that 3 months (vs 6 months) of adjuvant CAPOX (capecitabine and oxaliplatin) may be a potential treatment option for patients with high-risk colorectal...
Kai-Keen Shiu, MD, PhD, on Colorectal Cancer: Pembrolizumab vs Chemotherapy for Microsatellite Instability–High Disease
Kai-Keen Shiu, MD, PhD, of the University College Hospital NHS Foundation Trust - London, discusses an interim analysis of PFS 2 results (defined as time from random assignment to progression on the next line of therapy or death) from the phase III KEYNOTE-177 trial. This study has already shown...
Wasat Mansoor, MBChB, PhD, on Esophageal Cancer: Quality of Life With Pembrolizumab and Chemotherapy
Wasat Mansoor, MBChB, PhD, of The Christie NHS Foundation Trust, discusses phase III results from the KEYNOTE-590 trial, which showed no deterioration in health-related quality of life when pembrolizumab was added to chemotherapy in patients with metastatic and unresectable esophageal cancers...
Stereotactic Ablative Body Radiotherapy in Extracranial Oligometastatic Cancers
In a registry-based observational study reported in The Lancet Oncology, Chalkidou et al found that stereotactic ablative body radiotherapy (SABR) was associated with high overall survival and low rates of toxicity in patients with extracranial oligometastatic cancers. Study Details The prospective ...
Outcomes After Neoadjuvant Carboplatin/Paclitaxel in Women With Ovarian Cancer and Planned Delayed Surgery: ICON8 Analysis
In a post hoc analysis from the ICON8 trial reported in The Lancet Oncology, Morgan et al found evidence indicating that the evaluation of response to platinum-based neoadjuvant therapy in women with ovarian carcinoma using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, should...
Life and Death Under COVID-19
Victoria was a 79-year-old woman living alone in a London suburb. Having no children of her own, she visited us regularly here in the United States. She was one of three sisters and my sister-in-law. I knew her for more than 50 years, and she always reminded me of Audrey Hepburn, both in looks and ...
No Reduced Recurrence Risk With Perioperative Aromatase Inhibitor Use in HR-Positive Breast Cancer
In the UK phase III POETIC trial reported in The Lancet Oncology, Ian Smith, MD, of The Royal Marsden NHS Foundation Trust, London, and colleagues, found that perioperative aromatase inhibitor therapy did not reduce the risk of recurrence in postmenopausal women with hormone receptor (HR)-positive...
SABCS 2020: Radiotherapy Omission After Breast-Conserving Surgery for Older Patients With HR-Positive Breast Cancer
Patients aged 65 or older with hormone receptor (HR)-positive breast cancer who did not receive radiation therapy after breast-conserving surgery had higher rates of local recurrence but similar 10-year survival rates when compared to patients who received postoperative radiation therapy, according ...
No Reduction in Recurrence Risk With Perioperative Aromatase Inhibitor Therapy in Postmenopausal Patients With HR-Positive Breast Cancer
As reported in The Lancet Oncology by Ian E. Smith, MD, and colleagues, the phase III POETIC trial found that perioperative aromatase inhibitor therapy did not reduce the risk of disease recurrence in postmenopausal women with hormone receptor (HR)-positive early breast cancer vs no perioperative...
No Benefit of Adjuvant Sorafenib in Intermediate- or High-Risk Renal Cell Carcinoma
In a phase III trial (SORCE) reported in the Journal of Clinical Oncology, Tim Eisen, FMedSci, FRCP, PhD, of Cambridge University Hospitals NHS Foundation Trust, and colleagues found no disease-free survival benefit with 3 years of sorafenib vs placebo as adjuvant therapy in patients with renal...
Addition of Abemaciclib to Endocrine Therapy Improves Invasive Disease–Free Survival in High-Risk Early Breast Cancer
As reported in the Journal of Clinical Oncology by Stephen R.D. Johnston, MD, PhD, of the Royal Marsden NHS Foundation Trust, London, and colleagues, an interim analysis in the phase III monarchE trial has shown that adjuvant abemaciclib plus endocrine therapy significantly improved invasive...
COVID-19’s Impact on Cancer Care Around the World: Perspectives From the ASCO International Affairs Committee
As the world continues to respond to the COVID-19 pandemic, ASCO is committed to providing the most current information and resources to its members and the larger oncology community to help ensure that patients with cancer receive high-quality care. Here, members of the ASCO International Affairs...
No Biochemical Progression-Free Survival Benefit With Adjuvant vs Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer
As reported in The Lancet by Christopher C. Parker, MD, of Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, and colleagues, initial findings in the phase III RADICALS-RT trial have shown no biochemical progression-free survival benefit with adjuvant radiotherapy vs a policy of salvage...
Impact of COVID-19 on Well-Being in the Oncology Workforce: COVID-NOW Survey Results
The results of a survey of 1,038 doctors, nurses, pharmacists, administrators, and allied health professionals (such dietitians and physiotherapists) working in oncology in the United Kingdom’s National Health Service (NHS) during the spring wave of COVID-19 were presented by Susana N. Banerjee,...
UK-Based Study Finds Evidence of COVID-19 Infection, Antibody Presence in Oncology Health-Care Staff
A study of oncology staff carried out immediately after the spring peak of the COVID-19 pandemic in the United Kingdom indicated that many had been infected with the coronavirus, including those who did not show any symptoms. The study—presented by Favara et al at the NCRI (National Cancer Research ...
Intermittent Dosing Schedules of RAF/MEK Inhibitor in RAS/RAF-Mutant Solid Tumors and Multiple Myeloma
In a single-center phase I dose-escalation and basket dose-expansion study reported in The Lancet Oncology, Guo et al identified the phase II dose and schedule for the oral RAF/MEK inhibitor CH5126766 in patients with RAS/RAF-mutant cancers. The agent also showed antitumor activity across various...
Ipatasertib/Abiraterone Combination Shows Potential in Metastatic Castration-Resistant Prostate Cancer With PTEN Loss
Ipatasertib plus abiraterone plus prednisone achieved significantly superior radiographic progression–free survival and antitumor activity compared with placebo plus abiraterone plus prednisonein patients with metastatic castration-resistant prostate cancer and PTEN loss, according to the results...
Olaparib Improves Outcomes in Metastatic Castration-Resistant Prostate Cancer With BRCA1/2 Alterations
The PARP inhibitor olaparib reduced the risk of death by 31% compared with a second hormonal treatment (enzalutamide or abiraterone) in men with metastatic castration-resistant prostate cancer characterized by BRCA1, BRCA2, or ATM mutations, in the final analysis of the phase III PROfound trial...
Adjuvant Sorafenib vs Placebo in Patients With Kidney Cancer at Intermediate or High Risk of Relapse
In the phase III SORCE trial reported in the Journal of Clinical Oncology, Eisen et al found no benefit of sorafenib vs placebo as adjuvant therapy in patients with renal cell carcinoma at intermediate or high risk of disease recurrence. Study Details The double-blind trial included 1,711 patients...
Expert Point of View: Elizabeth Smyth, MD
The overall survival benefit for PD-L1 CPS ≥ 5 tumors in CheckMate 649 is a game-changer. An oxaliplatin doublet plus chemotherapy should become a standard of care for these patients,” according to Elizabeth Smyth, MD, an oncology consultant at Cambridge University Hospital NHS Foundation Trust in...
Nivolumab Plus Chemotherapy: New Standard of Care in Advanced Gastric Cancer?
As first-line treatment for advanced gastric cancer, nivolumab plus chemotherapy leads to significantly improved progression-free and overall survival over chemotherapy alone, investigators reported during a Presidential Symposium of the European Society for Medical Oncology (ESMO) Virtual Congress ...
Addition of Abemaciclib to Endocrine Therapy Reduces Recurrence in Early Breast Cancer
For the first time, an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) has reduced the risk of invasive disease recurrence in patients with early breast cancer when combined with standard endocrine therapy, investigators reported at the European Society for Medical Oncology (ESMO) Virtual...
Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With Early Breast Cancer at High Risk of Recurrence: monarchE Trial
As reported in the Journal of Clinical Oncology by Stephen R.D. Johnston, MD, PhD, and colleagues, the phase III monarchE trial has shown that adjuvant abemaciclib plus endocrine therapy significantly improved invasive disease–free survival vs endocrine therapy alone in patients with hormone...
SOLO1 5-Year Follow-up: Maintenance Olaparib for BRCA-Mutated Advanced Ovarian Cancer
Almost half of patients who received the PARP inhibitor olaparib for newly diagnosed BRCA-mutated advanced ovarian cancer remained disease-free after 5 years, according to data presented by Susana Banerjee, MBBS, PhD, and colleagues during the ESMO Virtual Congress 2020 (Abstract 811MO). Patients...
Stephen R.D. Johnston, MD, PhD, on Early Breast Cancer: Abemaciclib in High-Risk Disease
Stephen R.D. Johnston, MD, PhD, of The Royal Marsden NHS Foundation Trust, discusses phase III study findings from the global monarchE trial, which showed that when added to standard adjuvant endocrine therapy, abemaciclib is the first CDK4/6 inhibitor to improve invasive disease–free survival in...
Abemaciclib Plus Endocrine Therapy May Reduce Recurrence in Early Breast Cancer: monarchE Trial
For the first time, an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) has improved outcomes in patients with early breast cancer when combined with standard endocrine therapy, Stephen Johnston, MD, PhD, and colleagues reported at the ESMO Virtual Congress 2020 (Abstract LBA5_PR)....
Maintenance Avelumab Plus Best Supportive Care in Advanced Bladder Cancer
Findings from the JAVELIN Bladder 100 trial were published by Thomas Powles, MD, and colleagues in The New England Journal of Medicine. Researchers reported that the PD-L1 inhibitor avelumab led to a 31% reduction in risk of death, and extended median survival by more than 7 months in patients with ...
Updated Results of the ALTERNATIVE Trial of Lapatinib/Trastuzumab Plus AI in HER2-Positive, HR-Positive Metastatic Breast Cancer
Updated results of the phase III ALTERNATIVE trial of dual HER2 inhibition with lapatinib/trastuzumab plus aromatase inhibitor (AI) therapy in HER2-positive, hormone receptor (HR)-positive metastatic breast cancer were reported in the Journal of Clinical Oncology by Johnston et al. The previously...
Risk‐Reducing Early Salpingectomy and Delayed Oophorectomy Among Premenopausal Women
A study published by Gaba et al in BJOG: An International Journal of Obstetrics and Gynaecology has found that risk‐reducing early salpingectomy and delayed oophorectomy is highly acceptable among premenopausal women at increased risk for developing ovarian cancer—particularly among patients...
Managing Cancer in Older Adults During the COVID-19 Pandemic
The COVID-19 pandemic is an additional competing risk to factor in when making decisions about anticancer treatment for older adults. It poses a potential barrier to equal and evidence-based management of cancer in this group of patients. Implementing geriatric assessments in routine clinical...
Nationwide Trends Show Fewer Patients With Cancer in the United States Seeking Care Since Start of the COVID-19 Pandemic
Research published by London et al in JCO Clinical Cancer Informatics found significant decreases nationwide in the number of patients seen for cancer-related care as the COVID-19 pandemic progressed during the first few months of 2020. The most significant decline was seen in encounters related to ...
Modeling Study Aims to Estimate the Effect of the COVID-19 Pandemic on Cancer Deaths in England
In a population-based modeling study reported in The Lancet Oncology, Maringe et al estimated that delays in diagnosis due to the COVID-19 pandemic could result in 3,291 to 3,621 additional deaths from breast, colorectal, esophageal, and lung cancers within 5 years. As stated by the investigators,...
Are Patients With a Longer-Established Diagnosis of Cancer at Higher Risk for More Severe Infection or Death From COVID-19?
According to research published by Russell et al in Frontiers in Oncology, patients with a longer-established diagnosis of cancer are at increased risk for more severe infection with COVID-19, as well as death from the virus. Patients of Asian ethnicity or who were receiving palliative treatment...
